P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

• V. Pullarkat,
• A. Cruz-Chacon,
• S. Gangatharan,
• A. Melnyk,
• G. A. Palumbo,
• M. Bellini,
• S. K. Tantravahi,
• Q. Qin,
• J. Potluri,
• P. Vachhani

Affiliations

V. Pullarkat

1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States of America

A. Cruz-Chacon

2 Hospital Centro Comprensivo de Cancer Universidad de Puerto Rico, San Juan, Puerto Rico

S. Gangatharan

3 Department of Haematology, Fiona Stanley Hospital, University of Western Australia, Perth, Western Australia, Australia

A. Melnyk

4 Texas Oncology-Abilene, Abilene, TX, United States of America

G. A. Palumbo

5 Dipartimento di Science Mediche Chirurgiche e Tecnologie Avanzate “GF Ingrassia”, Università degli Studi di Catania, Catania

M. Bellini

6 ASST Papa Giovanni XXIII, Bergamo, Italy

S. K. Tantravahi

7 University of Utah and Huntsman Cancer Institute, Salt Lake City, UT

Q. Qin

8 AbbVie Inc., North Chicago, IL

J. Potluri

8 AbbVie Inc., North Chicago, IL

P. Vachhani

9 O’Neal Comprehensive Cancer Center at UAB, Birmingham, AL, United States of America